BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 17938645)

  • 1. HLA class II antigen presentation by prostate cancer cells.
    Younger AR; Amria S; Jeffrey WA; Mahdy AE; Goldstein OG; Norris JS; Haque A
    Prostate Cancer Prostatic Dis; 2008; 11(4):334-41. PubMed ID: 17938645
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recognition of a shared human prostate cancer-associated antigen by nonclassical MHC-restricted CD8+ T cells.
    Housseau F; Bright RK; Simonis T; Nishimura MI; Topalian SL
    J Immunol; 1999 Dec; 163(11):6330-7. PubMed ID: 10570328
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Forcing tumor cells to present their own tumor antigens to the immune system: a necessary design for an efficient tumor immunotherapy.
    Humphreys RE; Hillman GG; von Hofe E; Xu M
    Cell Mol Immunol; 2004 Jun; 1(3):180-5. PubMed ID: 16219165
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recognition of prostate and melanoma tumor cells by six-transmembrane epithelial antigen of prostate-specific helper T lymphocytes in a human leukocyte antigen class II-restricted manner.
    Kobayashi H; Nagato T; Sato K; Aoki N; Kimura S; Murakami M; Iizuka H; Azumi M; Kakizaki H; Tateno M; Celis E
    Cancer Res; 2007 Jun; 67(11):5498-504. PubMed ID: 17545632
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of human prostate and breast cancer cell lines for experimental T cell-based immunotherapy.
    Carlsson B; Forsberg O; Bengtsson M; Tötterman TH; Essand M
    Prostate; 2007 Mar; 67(4):389-95. PubMed ID: 17219382
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Loss of interferon-gamma inducibility of the MHC class II antigen processing pathway in head and neck cancer: evidence for post-transcriptional as well as epigenetic regulation.
    Meissner M; Whiteside TL; van Kuik-Romein P; Valesky EM; van den Elsen PJ; Kaufmann R; Seliger B
    Br J Dermatol; 2008 May; 158(5):930-40. PubMed ID: 18284388
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of HLA-DRB1*1501-restricted T-cell epitopes from human prostatic acid phosphatase.
    Klyushnenkova EN; Kouiavskaia DV; Kodak JA; Vandenbark AA; Alexander RB
    Prostate; 2007 Jul; 67(10):1019-28. PubMed ID: 17455230
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Numerical and functional assessment of blood dendritic cells in prostate cancer patients.
    Wilkinson R; Kassianos AJ; Swindle P; Hart DN; Radford KJ
    Prostate; 2006 Feb; 66(2):180-92. PubMed ID: 16173035
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rebuilding human leukocyte antigen class II-restricted minor histocompatibility antigen specificity in recall antigen-specific T cells by adoptive T cell receptor transfer: implications for adoptive immunotherapy.
    Spaapen R; van den Oudenalder K; Ivanov R; Bloem A; Lokhorst H; Mutis T
    Clin Cancer Res; 2007 Jul; 13(13):4009-15. PubMed ID: 17606735
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reduced human leukocyte antigen expression in advanced-stage Ewing sarcoma: implications for immune recognition.
    Berghuis D; de Hooge AS; Santos SJ; Horst D; Wiertz EJ; van Eggermond MC; van den Elsen PJ; Taminiau AH; Ottaviano L; Schaefer KL; Dirksen U; Hooijberg E; Mulder A; Melief CJ; Egeler RM; Schilham MW; Jordanova ES; Hogendoorn PC; Lankester AC
    J Pathol; 2009 Jun; 218(2):222-31. PubMed ID: 19274709
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Turning tumor cells in situ into T-helper cell-stimulating, MHC class II tumor epitope-presenters: immuno-curing and immuno-consolidation.
    Hillman GG; Kallinteris NL; Lu X; Wang Y; Wright JL; Li Y; Wu S; Forman JD; Gulfo JV; Humphreys RE; Xu M
    Cancer Treat Rev; 2004 May; 30(3):281-90. PubMed ID: 15059651
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Control of T-cell-mediated immune response by HLA class I in human pancreatic carcinoma.
    Ryschich E; Nötzel T; Hinz U; Autschbach F; Ferguson J; Simon I; Weitz J; Fröhlich B; Klar E; Büchler MW; Schmidt J
    Clin Cancer Res; 2005 Jan; 11(2 Pt 1):498-504. PubMed ID: 15701833
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Induction of EBV-latent membrane protein 1-specific MHC class II-restricted T-cell responses against natural killer lymphoma cells.
    Kobayashi H; Nagato T; Takahara M; Sato K; Kimura S; Aoki N; Azumi M; Tateno M; Harabuchi Y; Celis E
    Cancer Res; 2008 Feb; 68(3):901-8. PubMed ID: 18245493
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Localization and MHC class II presentation of antigens targeted for macroautophagy.
    Schmid D; Münz C
    Methods Mol Biol; 2008; 445():213-25. PubMed ID: 18425453
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advances in specific immunotherapy for prostate cancer.
    Kiessling A; Füssel S; Wehner R; Bachmann M; Wirth MP; Rieber EP; Schmitz M
    Eur Urol; 2008 Apr; 53(4):694-708. PubMed ID: 18061335
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structural principles of MHC class II antigen presentation.
    Nelson CA; Fremont DH
    Rev Immunogenet; 1999; 1(1):47-59. PubMed ID: 11256572
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The induction of tumor-specific CD4+ T cells via major histocompatibility complex class II is required to gain optimal anti-tumor immunity against B16 melanoma cell line in tumor immunotherapy using dendritic cells.
    Fujisawa Y; Nabekura T; Nakao T; Nakamura Y; Takahashi T; Kawachi Y; Otsuka F; Onodera M
    Exp Dermatol; 2009 Apr; 18(4):396-403. PubMed ID: 19054057
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Major histocompatibility antigens and antigen-processing molecules in retinoblastoma.
    Krishnakumar S; Sundaram A; Abhyankar D; Krishnamurthy V; Shanmugam MP; Gopal L; Sharma T; Biswas J
    Cancer; 2004 Mar; 100(5):1059-69. PubMed ID: 14983503
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Contrasting cytoskeletal regulation of MHC class II peptide presentation by human B cells or dendritic cells.
    Delaguillaumie A; Marin-Esteban V; Setterblad N; Leh LJ; Assier E; Gelin C; Charron D; Galy A; Mooney N
    Eur J Immunol; 2008 Apr; 38(4):1096-105. PubMed ID: 18393378
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A role for the Hsp90 molecular chaperone family in antigen presentation to T lymphocytes via major histocompatibility complex class II molecules.
    Rajagopal D; Bal V; Mayor S; George A; Rath S
    Eur J Immunol; 2006 Apr; 36(4):828-41. PubMed ID: 16552710
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.